GEN.CO - Genmab A/S

Copenhagen - Copenhagen Real Time Price. Currency in DKK
1,122.00
-5.00 (-0.44%)
At close: 4:59PM CEST
Stock chart is not supported by your current browser
Previous Close1,127.00
Open1,127.00
Bid1,122.50 x 0
Ask1,123.50 x 0
Day's Range1,116.00 - 1,131.50
52 Week Range786.20 - 1,335.00
Volume118,382
Avg. Volume177,815
Market Cap69.195B
Beta (3Y Monthly)0.78
PE Ratio (TTM)47.28
EPS (TTM)23.73
Earnings DateMay 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1,284.65
  • GlobeNewswire4 days ago

    Genmab Announces Data to be Presented at 2019 ASCO Annual Meeting

    Media Release Copenhagen, Denmark, April 17, 2019 14 industry sponsored abstracts regarding Genmab programs selected for presentation at ASCO Annual Meeting Genmab A/S (Nasdaq.

  • GlobeNewswire6 days ago

    Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2019

    Genmab will receive royalties on worldwide sales from Janssen Biotech, Inc. April 16, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that worldwide net sales of DARZALEX (daratumumab) as reported by Johnson & Johnson were USD 629 million in the first quarter of 2019. Net sales were USD 352 million in the U.S. and USD 277 million in the rest of the world.

  • Will Genmab A/S's (CPH:GEN) Earnings Grow In The Next Couple Of Years?
    Simply Wall St.17 days ago

    Will Genmab A/S's (CPH:GEN) Earnings Grow In The Next Couple Of Years?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The latest earnings update Genmab A/S (CPH:GEN) released in December 2018 confirmed that...

  • GlobeNewswire17 days ago

    Genmab Announces Submission of Supplemental New Drug Application in Japan for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

    Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Janssen Pharmaceutical K.K. has submitted a supplemental new drug application (sNDA) to the Ministry of Health, Labor and Welfare (MHLW) in Japan, for the use of daratumumab (DARZALEX®) in combination with lenalidomide and dexamethasone (Rd) as treatment for patients newly diagnosed with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem cell transplant (ASCT). The MHLW will grant a priority review of the application, based on the Orphan Drug Designation given to DARZALEX for patients with newly diagnosed multiple myeloma.

  • GlobeNewswire19 days ago

    Genmab Announces Phase III Study Exploring Daratumumab as Maintenance Treatment in Newly Diagnosed Multiple Myeloma

    Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its collaboration partner, Janssen Biotech, Inc. (“Janssen”) plans to start a new Phase III study of daratumumab in multiple myeloma. The study (MMY3021) will compare subcutaneous daratumumab in combination with lenalidomide versus lenalidomide alone as maintenance treatment in patients with newly diagnosed multiple myeloma who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT).

  • GlobeNewswire19 days ago

    Capital Increase in Genmab as a Result of Employee Warrant Exercise

    Company Announcement Copenhagen, Denmark; April 2, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 146,961 shares as a consequence of the exercise.

  • GlobeNewswire20 days ago

    Genmab to Present at the H.C. Wainwright & Co. Global Life Sciences Conference

    Media Release Copenhagen, Denmark, April 2, 2019 Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at.

  • GlobeNewswire23 days ago

    Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab

    Following Genmab A/S’ (Nasdaq Copenhagen: GEN) Annual General Meeting held on March 29, 2019, the Company’s Board of Directors met to constitute itself. It was decided to grant 2,570 restricted stock units and 8,035 warrants to employees of the Company and two of the Company’s subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1.

  • GlobeNewswire24 days ago

    Passing of Genmab A/S’ Annual General Meeting

    Company Announcement At Genmab A/S’ Annual General Meeting held today March 29, 2019, the Annual Report for 2018 was approvedDischarge was given to the Board of Directors and.

  • GlobeNewswire26 days ago

    Genmab Announces European Regulatory Submission for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

    Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Janssen Pharmaceutica NV (Janssen) has submitted a Type II variation application to the European Medicines Agency (EMA). This application seeks to broaden the existing marketing authorization for daratumumab (DARZALEX®) to include use in combination with bortezomib, thalidomide and dexamethasone (VTD) as treatment for newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant (ASCT).

  • GlobeNewswire27 days ago

    Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

    Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its licensing partner, Janssen Biotech, Inc., has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (U.S. FDA) for the use of daratumumab (DARZALEX®) in combination with bortezomib, thalidomide and dexamethasone (VTD) as treatment for newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant (ASCT). In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab.

  • GlobeNewswirelast month

    Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

    Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Janssen Pharmaceutica NV (Janssen) has submitted a Type II variation application to the European Medicines Agency (EMA). The application seeks to broaden the existing marketing authorization for daratumumab (DARZALEX®) to include use in combination with lenalidomide and dexamethasone (Rd) as treatment for newly diagnosed multiple myeloma patients who are not candidates for high dose chemotherapy and autologous stem cell transplant (ASCT).

  • GlobeNewswirelast month

    Genmab Announces Appointment of Marisol Peron as Head of Communications and Investor Relations

    Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Marisol Peron has been appointed Corporate Vice President, Communications and Investor Relations, effective March 11, 2019. Ms. Peron will be responsible for the strategic management of both internal and external communications and investor relations efforts for Genmab.

  • GlobeNewswire2 months ago

    Grant of Restricted Stock Units and Warrants to Employees in Genmab

    Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 6,397 restricted stock units and 19,982 warrants to employees of the company and two of the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,161.

  • GlobeNewswire2 months ago

    Genmab A/S Summons Annual General Meeting

    Genmab A/S (Nasdaq Copenhagen: GEN) summons the Annual General Meeting on Friday, March 29, 2019 at 11:00 AM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. Presentation and adoption of the audited Annual Report 2018 and resolution to discharge the Board of Directors and the Executive Management from liability.

  • GlobeNewswire2 months ago

    Genmab Announces Positive Topline Results in Phase III COLUMBA Study of Subcutaneous Daratumumab

    Genmab A/S (Nasdaq Copenhagen: GEN) announced today topline results from the Phase III COLUMBA study (MMY3012) of subcutaneous (SC) versus intravenous (IV) daratumumab for patients with relapsed or refractory multiple myeloma. The results showed that SC administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 is non-inferior to IV administration of daratumumab with regard to the co-primary end points of overall response rate (ORR) and Maximum Trough concentration (Ctrough) of daratumumab on day 1 of the third treatment cycle.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of GEN.CO earnings conference call or presentation 20-Feb-19 5:00pm GMT

    Q4 2018 Genmab A/S Earnings Call

  • Reuters2 months ago

    Poor results drag European shares down from four-month highs

    MILAN/LONDON (Reuters) - European shares dipped on Thursday, weighed down by several weak earnings updates and after data showed that euro zone factory output unexpectedly fell last month. Euro zone factory output slammed into reverse last month as activity in Germany declined again amid trade tensions and struggles in the auto sector, surveys showed. "There is still widespread concern about how well the economy in Europe has been performing in recent months," said Michael Hewson, chief market analyst at CMC Markets.

  • What Kind Of Shareholder Appears On The Genmab A/S’s (CPH:GEN) Shareholder Register?
    Simply Wall St.2 months ago

    What Kind Of Shareholder Appears On The Genmab A/S’s (CPH:GEN) Shareholder Register?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! A look at the shareholders of Genmab A/S (CPH:GEN) canRead More...

  • GlobeNewswire2 months ago

    Genmab 2018 Annual Report

    Company Announcement Copenhagen, Denmark; February 20, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today its Annual Report for 2018.  Below is a summary of.

  • GlobeNewswire2 months ago

    Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) Split Dosing Regimen

    Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved a split dosing regimen for DARZALEX® (daratumumab).  The approval will be included in an update to the Prescribing Information in order to provide healthcare professionals the option to split the first infusion of DARZALEX over two consecutive days. The supplemental Biologics License Application (sBLA) was submitted by Genmab’s licensing partner, Janssen Biotech, Inc., in July, 2018.

  • GlobeNewswire3 months ago

    Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over

    Company Announcement Genmab, Janssen and MorphoSys have agreed to end the patent infringement lawsuit launched by MorphoSys AG relating to DARZALEXOn January 25, 2019, a.

  • What Should We Expect From Genmab A/S’s (CPH:GEN) Earnings Over The Next Year?
    Simply Wall St.3 months ago

    What Should We Expect From Genmab A/S’s (CPH:GEN) Earnings Over The Next Year?

    In September 2018, Genmab A/S (CPH:GEN) announced its earnings update. Overall, it seems that analyst expectations are fairly bearish, with profits predicted to rise by 17% next year relative to Read More...

  • Big losses for European stocks as Caterpillar, China disappoint
    Reuters3 months ago

    Big losses for European stocks as Caterpillar, China disappoint

    By Julien Ponthus and Helen Reid LONDON (Reuters) - European shares slid on Monday as optimism about the end of a U.S. government shutdown faded and growth worries reared their head again. The pan-European ...